CHARGED ALPHATMFrontier AI stock research

ATAI · NGM

AtaiBeckley Inc.

Biotechnology · United States

USD 7.350.0% daily changeQuote 2026-09-10 · USD
Market cap (USD)
US$2.73B
Trailing P/E
—
Forward P/E
—
Quarterly revenue growth
137.0%
Trailing net margin
0.0%
Indicated dividend yield
—

Snapshot 2026-10-06 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.

Company background

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments. The company develops rapid-acting and durable therapies for conditions with limited treatment options. Its pipeline includes BPL-003 (mebufotenin benzoate), an intranasal formulation in Phase 2 and 3 clinical studies for treatment-resistant depression and alcohol use disorder; ELE-101, a serotonergic psychedelic for major depressive disorder; and RL-007, an orally bioavailable pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia. The company's pipeline also comprises VLS-01, an oral transmucosal film formulation of N, N-Dimethyltryptamine in Phase 2 clinical study for treatment-resistant depression; EMP-01, an oral formulation of the R-enantiomer of 3,4-methylenedioxy-methamphetamine in Phase 2 clinical study for social anxiety disorder; and EGX-A and EGX-B, non-hallucinogenic 5-HT2A receptor agonists for treatment-resistant depression. Additionally, it offers COMP360, a psilocybin therapy; and GRX-917, a treatment for anxiety, depression, and various neurological disorders. The company has additional operations in Germany and Canada. AtaiBeckley Inc. was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York. AtaiBeckley Inc. operates as a subsidiary of Eli Lilly and Company.

Company website

Q4 2025

Go beyond the headline.

ATAI (ATAI) Earnings: Cash Runway Extends as Trials Move Forward | Q42025

Published 2026-04-20

Comparable businesses

ATAI peer comparison

Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.

Comparison stocks

No suitable peers with fresh, comparable size data are available. We have not substituted unrelated companies.

Market metrics · missing or inapplicable values shown as —
MetricATAIAtaiBeckley Inc.Snapshot 2026-10-06Financial period: 2026-06-30
Market capMarket value, converted to USDUS$2.73B
Forward P/EProvider forward earnings estimate—
EV / EBITDAEnterprise value / trailing EBITDA—
Revenue growthLatest quarter vs prior-year quarter137.0%
Operating marginLatest reported quarter-2,590.4%
Free cash flow yieldTrailing cash flow / market cap-2.7%
Net debt / EBITDANet debt / trailing EBITDA—
Debt / equityTotal debt / positive book equity0.02x
Trailing P/ETrailing twelve-month earnings—
Price / bookPrice / positive book equity per share15.38x
EV / salesEnterprise value / trailing revenue560.02x
Earnings growthLatest quarter vs prior-year quarter—
Gross marginTrailing twelve months0.0%
Net marginTrailing twelve months0.0%
Return on equityProvider trailing return; positive equity only-417.2%
Free cash flow marginTrailing free cash flow / revenue-1,669.7%
Dividend yieldIndicated annual dividend / price—
Earnings payoutProvider trailing dividend payout0.0%
Current ratioCurrent assets / current liabilities8.58x
BetaProvider historical market sensitivity1.55

Choose a comparison stock

Search covered companies, or search all listed stocks.

Comparison methodology & limitations

Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.

Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.

Reported performance

Financial trends

Reporting period
Financial history
Chart style
Comparison stocks

Financial statements load separately from the research page.

Market context

Valuation & price history

Adjusted closing price

Price history

Price history loads separately.

Earnings-multiple scenario

Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.

Starting assumptions, when available, use provider forward estimates as of 2026-10-06. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.

THE RESEARCH RECORD

Research history for ATAI

All available reporting periods
Q4 20252026-04-20
Deep Dive2026-04-19

Reported figures

Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.